Connor, Clark & Lunn Investment Management Ltd. Akero Therapeutics, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $26 Billion
- Q2 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 41,328 shares of AKRO stock, worth $2.23 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
41,328Holding current value
$2.23 Million% of portfolio
0.01%Shares
9 transactions
Others Institutions Holding AKRO
# of Institutions
298Shares Held
92.4MCall Options Held
1.72MPut Options Held
901K-
Janus Henderson Group PLC London, X06.74MShares$364 Million0.19% of portfolio
-
General Atlantic LLC New York, NY5.73MShares$309 Million10.64% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$301 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$296 Million4.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.53MShares$244 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.5B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...